Sign In
Buy SVA
$6.47
+0 (+0%)
At Close: Feb 07, 2020
Vivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board's Value Destructive Actions
09:00pm, Wednesday, 23'rd Apr 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or the “Firm”), a leading global investment firm focused exclusively on healthcare and life sciences, today announced multiple legal pr
SINOVAC Management Statement Regarding Auditor Resignation
12:06am, Tuesday, 22'nd Apr 2025
Beijing, April 22, 2025 (GLOBE NEWSWIRE) -- To the Shareholders of Sinovac Biotech Ltd. and Other Stakeholders: The management of Sinovac Biotech Ltd.
BOSTON , April 10, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Partners, LLC sent a letter on April 8, 2025, to Sinovac's Board calling on the Board to disclose the re
SINOVAC Announces Decision to Declare Cash Dividend
12:48am, Tuesday, 01'st Apr 2025
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company's board o
SINOVAC Announces New Board Member and Chairman of the Audit Committee
07:00am, Friday, 28'th Mar 2025
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the �
Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
11:05am, Thursday, 20'th Mar 2025
BOSTON , March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlini
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order
07:00am, Friday, 28'th Feb 2025
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on Februa
SINOVAC Issues Statement Regarding Privy Council Judgment
08:01am, Thursday, 16'th Jan 2025
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of the
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
05:04am, Monday, 16'th Dec 2024
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phas
SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
05:53pm, Monday, 29'th Apr 2024
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 2
Sinovac Amends Shareholder Rights Plan
02:56am, Wednesday, 21'st Feb 2024
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of director
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
07:00am, Thursday, 18'th Jan 2024
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that its Board of Director
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
05:55am, Monday, 11'th Sep 2023
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed t
Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer
04:12am, Tuesday, 05'th Sep 2023
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that its Board of Director
Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer
03:07am, Tuesday, 29'th Aug 2023
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an uns
